Evidence map›Paper›PMID 35456340›Full record

ArticleJournal of clinical medicine2022

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.

Toshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, Yusuke Kurioka, Keitaro Doi, Shogen Boku, Nobuhiro Shibata, Hiroki Nagai, Takanobu Shimada, Takao Tsuduki and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  4. Article
  5. Article
  6. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Toshihiko MatsumotoDepartment of Medical Oncology, Kobe City Medical Center General Hospital, 2-1-1, Minatojimaminamimachi, Kobe 6500047, Japan.ORCID 0000-0002-7397-1006
Shogo YamamuraDepartment of Medical Oncology, Kobe City Medical Center General Hospital, 2-1-1, Minatojimaminamimachi, Kobe 6500047, Japan.
Tatsuki IkomaDepartment of Clinical Oncology, Osaka Red Cross Hospital, 5-30, Tenoji-ku, Fudegasakicho, Osaka 5438555, Japan.ORCID 0000-0003-3758-3425
Yusuke KuriokaDepartment of Internal Medicine, Himeji Red Cross Hospital, 1-12-1, Shimoteno, Himeji 6708540, Japan.
Keitaro DoiDepartment of Clinical Oncology, Osaka Red Cross Hospital, 5-30, Tenoji-ku, Fudegasakicho, Osaka 5438555, Japan.
Shogen BokuCancer Treatment Center, Kansai Medical University, 2-3-1, Shinmachi, Hirakata 5731191, Japan.ORCID 0000-0002-5015-0379
Nobuhiro ShibataCancer Treatment Center, Kansai Medical University, 2-3-1, Shinmachi, Hirakata 5731191, Japan.ORCID 0000-0001-8647-5098
Hiroki NagaiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, 2-1-1, Minatojimaminamimachi, Kobe 6500047, Japan.
Takanobu ShimadaDepartment of Clinical Oncology, Osaka Red Cross Hospital, 5-30, Tenoji-ku, Fudegasakicho, Osaka 5438555, Japan.ORCID 0000-0002-5338-6002
Takao TsudukiDepartment of Internal Medicine, Himeji Red Cross Hospital, 1-12-1, Shimoteno, Himeji 6708540, Japan.
Takehiko TsumuraDepartment of Clinical Oncology, Osaka Red Cross Hospital, 5-30, Tenoji-ku, Fudegasakicho, Osaka 5438555, Japan.
Masahiro TakataniDepartment of Internal Medicine, Himeji Red Cross Hospital, 1-12-1, Shimoteno, Himeji 6708540, Japan.
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, 2-1-1, Minatojimaminamimachi, Kobe 6500047, Japan.
Hironaga SatakeDepartment of Medical Oncology, Kobe City Medical Center General Hospital, 2-1-1, Minatojimaminamimachi, Kobe 6500047, Japan.ORCID 0000-0001-7629-6803
Kansai Medical University · JPOsaka Red Cross Hospital · JPHimeji Red Cross Hospital · JPKobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab deruxtecan (T-DXd) has shown promising efficacy against

Indexed as

chemotherapygastric cancerreal-world dataT-DXdtrastuzumab deruxtecan

Identifiers

PMID35456340
PMCPMC9030612
OpenAlexW4224126593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.